Evidence map›Paper›PMID 41353615›Full record

ArticleACS applied materials & interfaces2025

Double-Network Polysaccharide-Collagen Hybrid Bioink.

Fabian Tribukait-Riemenschneider, V Prasad Shastri

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fabian Tribukait-RiemenschneiderInstitute for Macromolecular Chemistry, University of Freiburg,Freiburg 79104, Germany.ORCID 0000-0002-6669-7862
V Prasad ShastriInstitute for Macromolecular Chemistry and BIOSS - Centre for Biological Signalling Studies, University of Freiburg, Freiburg 79104, Germany.ORCID 0000-0001-5125-9678

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, three-dimensional bioprinting (3DBP) has evolved into a versatile processing tool for engineering tissues. The key component, the bioink, can be composed of many different hydrogel-forming polymers, which are mostly performant in either mechanical or biological properties but seldom both. Carboxylated agarose (CA) was combined here with collagen type 1 to simultaneously satisfy both properties and combine their attributes, without compromising on either; the result is an innovative, hybrid bioink. It can be printed with high accuracy, good layer-to-layer adhesion, and rapid gelation, enabling overhang printing. Scanning electron microscopy (SEM) and fluorescently labeled collagen demonstrated that the two components mixed well, resulting in uniformly distributed collagen fibrils and a double network. From the biological perspective, a bioink must exhibit cell-adhesion moieties to maintain proliferation and metabolism, which we could ensure through the collagen component. Here, we present an example strategy for combining an inert polysaccharide with bioactive collagen, two polymers with opposing gelation conditions, which yields a bioink that possesses beneficial properties from both without compromising the features of either. The interpenetrating structure of both molecules synergistically balances the mechanical strength of CA and the biological functionality of collagen.

Indexed as

Biocompatible MaterialsBioprintingCollagenInkPolysaccharidesSepharoseAnimalsHumansHydrogelsPrinting, Three-DimensionalTissue EngineeringTissue ScaffoldsBiocompatible MaterialsCollagenHydrogelsPolysaccharidesSepharose3D bioprintingcarboxylated agarosecollagenhybrid bioinkinterpenetrating network

Identifiers

PMID41353615
PMCPMC12723644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.